[C:1](O)([C:3](F)(F)F)=[O:2].[NH2:8][C:9]1[C:10]([C:26]([NH2:28])=[O:27])=[CH:11][C:12]2[C:20]3[C:15](=[CH:16][CH:17]=[CH:18][CH:19]=3)[N:14]([CH2:21][C@@H:22]([NH2:24])[CH3:23])[C:13]=2[N:25]=1>>[C:1]([NH:8][C:9]1[C:10]([C:26]([NH2:28])=[O:27])=[CH:11][C:12]2[C:20]3[C:15](=[CH:16][CH:17]=[CH:18][CH:19]=3)[N:14]([CH2:21][C@@H:22]([NH2:24])[CH3:23])[C:13]=2[N:25]=1)(=[O:2])[CH3:3]xxxi-a (44 mg, 0.104 mmol) was deprotected using the TFA conditions detailed in the preparation of 30 to afford the title compound (66, 29 mg, 63%). NH4OAc standard conditions. DAD